The United States Pharmacopeial Convention has released Prednisone Tablets Reference Standard lot Q0H398 (Q0) to replace lot P1I300 (P1) for performance verification testing of dissolution Apparatus 1 and 2 as mandated by United States Pharmacopeia General Chapter Dissolution <711>. This report presents the collaborative study data, development of the acceptance limits, and results from supporting work for this lot. The collaborative study involved 21 collaborators who provided data for both Apparatus 1 and Apparatus 2. The study also evaluated the stability of Lot Q0 based on the dissolution results using Apparatus 1 and 2. The authors determined the geometric mean and percent coefficient of variation acceptance limits for 6-, 7-, 8-, 12-, and 14-position dissolution testers. The results of the collaborative study were used to establish the acceptance limits for the PVT for Apparatus 1 and 2 using lot Q0. Analysts found similarity in the data as well as in the acceptance limits for lots Q0 and P1, and dissolution results for Lot Q0 with Apparatus 1 appear to be stable. As with Lot P1, the dissolution results for Lot Q0 with Apparatus 2 show some decrease over time, and the geometric mean acceptance limits were adjusted accordingly. Results yielded acceptance limits for Apparatus 1 and Apparatus 2 that are different from those for Lot P1-but not markedly so-and are suitable for continued use in the PVT.